Profile data is unavailable for this security.
About the company
Context Therapeutics Inc. is a biopharmaceutical company advancing medicines for solid tumors. The Company is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors, which is in preclinical development. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, endometrial, testicular, and lung, and absent from or expressed at low levels in healthy adult tissues. CTIM-76 is capable of binding to tumor cells expressing CLDN6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement while silent elsewhere. CTIM-76 has the potential for a wide therapeutic window, which is the difference between the dose required for the intended therapeutic effect and the dose required to elicit an unwanted side effect.
- Revenue in USD (TTM)0.00
- Net income in USD-23.96m
- Incorporated2015
- Employees5.00
- LocationContext Therapeutics Inc2001 Market Street, Suite 3915 Unit #15PHILADELPHIA 19103United StatesUSA
- Phone+1 (267) 225-7416
- Fax+1 (302) 655-5049
- Websitehttps://www.contexttherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unity Biotechnology Inc | 0.00 | -39.86m | 27.03m | 19.00 | -- | 0.9516 | -- | -- | -2.75 | -2.75 | 0.00 | 1.69 | 0.00 | -- | -- | 0.00 | -41.95 | -47.21 | -49.03 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| Acasti Pharma Inc | 0.00 | -38.77m | 27.82m | 32.00 | -- | 0.4302 | -- | -- | -5.06 | -5.06 | 0.00 | 6.88 | 0.00 | -- | -- | -- | -40.18 | -45.71 | -41.30 | -50.84 | -- | -- | -- | -69,798.47 | -- | -14.38 | 0.00 | -- | -- | -- | -332.11 | -- | -45.53 | -- |
| Aptorum Group Ltd | 1.20m | -13.40m | 28.91m | 18.00 | -- | 1.32 | -- | 24.10 | -3.64 | -3.64 | 0.3234 | 4.22 | 0.0624 | 74.87 | 17.36 | 66,656.11 | -80.15 | -42.74 | -68.67 | -46.93 | 7.33 | -2.90 | -1,283.55 | -1,477.58 | 1.32 | -94.53 | 0.0066 | -- | -15.95 | -- | 60.88 | -- | -42.83 | -- |
| Aprea Therapeutics Inc | 583.24k | -14.29m | 29.05m | 7.00 | -- | 1.18 | -- | 49.81 | -4.00 | -4.00 | 0.1613 | 4.89 | 0.0221 | -- | -- | 83,320.00 | -54.11 | -68.66 | -63.19 | -77.19 | -- | -- | -2,449.55 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
| RenovoRx Inc | 0.00 | -10.23m | 29.22m | 8.00 | -- | -- | -- | -- | -1.01 | -1.01 | 0.00 | -0.2805 | 0.00 | -- | -- | 0.00 | -234.38 | -- | -317.07 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -3.47 | -- | -- | -- |
| Context Therapeutics Inc | 0.00 | -23.96m | 29.54m | 5.00 | -- | 2.49 | -- | -- | -1.50 | -1.50 | 0.00 | 0.7435 | 0.00 | -- | -- | 0.00 | -88.71 | -- | -102.79 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| Singular Genomics Systems Inc | 2.91m | -94.82m | 30.54m | 255.00 | -- | 0.1704 | -- | 10.49 | -1.30 | -1.30 | 0.04 | 2.42 | 0.0098 | 0.2182 | 3.94 | 11,415.69 | -31.96 | -- | -33.80 | -- | -19.17 | -- | -3,257.30 | -- | 9.77 | -- | 0.0474 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
| Spruce Biosciences Inc | 10.09m | -47.92m | 30.63m | 29.00 | -- | 0.3992 | -- | 3.04 | -1.26 | -1.26 | 0.2622 | 1.86 | 0.1064 | -- | -- | 347,896.60 | -50.55 | -41.24 | -62.77 | -46.49 | -- | -- | -474.96 | -1,774.39 | -- | -107.65 | 0.0418 | -- | -- | -- | -3.77 | -- | -- | -- |
| Dare Bioscience Inc | 2.81m | -30.16m | 31.30m | 23.00 | -- | -- | -- | 11.15 | -0.3444 | -0.3444 | 0.032 | -0.0505 | 0.0863 | -- | 2.12 | 122,082.20 | -92.65 | -109.51 | -463.87 | -246.26 | -- | -- | -1,074.17 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| Earth Science Tech Inc | 5.98m | 330.94k | 31.49m | 8.00 | 104.17 | 14.59 | 59.49 | 5.26 | 0.001 | 0.001 | 0.0195 | 0.0069 | 3.16 | 11.41 | 106.07 | 747,970.00 | 17.50 | -224.84 | 42.70 | -- | 62.29 | 37.79 | 5.53 | -333.58 | 0.386 | -0.3899 | 0.1023 | -- | 243.77 | -36.31 | -111.95 | -- | -- | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.08m | 31.75m | 2.00 | -- | -- | -- | -- | -0.0327 | -0.0327 | 0.00 | -0.0416 | 0.00 | -- | -- | 0.00 | -364.66 | -- | -- | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- | -- | -317.25 | -- | -- | -- |
| Viracta Therapeutics Inc | 0.00 | -51.06m | 31.82m | 40.00 | -- | 2.46 | -- | -- | -1.32 | -1.32 | 0.00 | 0.4686 | 0.00 | -- | -- | 0.00 | -66.88 | -86.35 | -97.91 | -106.38 | -- | -- | -- | -11,853.94 | -- | -141.21 | 0.5798 | -- | -- | -- | -3.78 | -- | -- | -- |
| Surrozen Inc | 0.00 | -43.04m | 31.99m | 42.00 | -- | 0.5438 | -- | -- | -21.35 | -21.35 | 0.00 | 18.39 | 0.00 | -- | -- | 0.00 | -63.52 | -- | -72.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
Data as of May 06 2024. Currency figures normalised to Context Therapeutics Inc's reporting currency: US Dollar USD
17.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Opaleye Management, Inc.as of 31 Dec 2023 | 975.00k | 6.11% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 596.01k | 3.73% |
| Affinity Asset Advisors LLCas of 31 Dec 2023 | 328.82k | 2.06% |
| UBS O'Connor LLCas of 31 Dec 2023 | 296.68k | 1.86% |
| swisspartners Marcuard Heritage AGas of 30 Jun 2023 | 260.00k | 1.63% |
| HighTower Advisors LLCas of 31 Dec 2023 | 125.85k | 0.79% |
| Bridgeway Capital Management LLCas of 31 Dec 2023 | 105.81k | 0.66% |
| Geode Capital Management LLCas of 31 Dec 2023 | 97.24k | 0.61% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 37.22k | 0.23% |
| Clear Harbor Asset Management LLCas of 31 Dec 2023 | 36.00k | 0.23% |
More ▼
Data from 30 Jun 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
